RT Journal Article
SR Electronic
T1 Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.19.20234153
DO 10.1101/2020.11.19.20234153
A1 Garibaldi, Brian T.
A1 Wang, Kunbo
A1 Robinson, Matthew L.
A1 Zeger, Scott L.
A1 Roche, Karen Bandeen
A1 Wang, Mei-Cheng
A1 Alexander, G. Caleb
A1 Gupta, Amita
A1 Bollinger, Robert
A1 Xu, Yanxun
YR 2020
UL http://medrxiv.org/content/early/2020/11/20/2020.11.19.20234153.abstract
AB Rationale Remdesivir and dexamethasone reduced the severity of COVID-19 in clinical trials. However, their individual or combined effectiveness in clinical practice remains unknown.Objectives To examine the effectiveness of remdesivir with or without dexamethasone.Methods We conducted a multicenter, retrospective cohort study between March 4 and August 29, 2020. Eligible COVID cases were hospitalized patients treated with remdesivir with or without dexamethasone. We applied a Cox proportional hazards model with propensity score matching to estimate the effect of these treatments on clinical improvement by 28 days (discharge or a 2-point decrease in WHO severity score) and 28-day mortality.Measurements and Main Results Of 2485 COVID-19 patients admitted between March 4 and August 29, 2020, 342 received remdesivir and 157 received remdesivir plus dexamethasone. Median age was 60 years; 45% were female; 81% were non-white. Remdesivir recipients on room air or nasal cannula oxygen had a faster time to clinical improvement (median 5.0 days [IQR 4.0, 8.0], remdesivir vs. 7.0 days [IQR 5.0, 12.0], control; adjusted hazard ratio (aHR) 1.55 [1.28; 1.87]), yet those requiring higher levels of respiratory support did not benefit. Remdesivir recipients had lower, but statistically insignificant, 28-day mortality (7.6% [23 deaths], remdesivir vs. 14.9% [45 deaths], control). Adding dexamethasone trended toward lower 28-day mortality compared to remdesivir alone (5.1% [8 deaths] vs. 9.2% [17 deaths]; aHR 0.14 [0.02; 1.03]).Conclusions Remdesivir offered a significantly faster time to clinical improvement among a cohort of predominantly non-white patients hospitalized with COVID-19, particularly with mild-moderate disease. Remdesivir plus dexamethasone may reduce mortality.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form and declare: Dr Alexander has served as a paid advisor to IQVIA, is a cofounding Principal and equity holder in Monument Analytics, is a member of the OptumRx National P and T Committee, and former Chair of the Food and Drug Administration Peripheral and Central Nervous System Advisory Committee. These arrangements have been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.Funding StatementThis work was supported by funding from Hopkins inHealth, the Johns Hopkins Precision Medicine Program through JH-CROWN and the COVID-19 Administrative Supplement for the HHS Region 3 Treatment Center from the Office of the Assistant Secretary for Preparedness and Response (to BTG, KW, MR, AG and YX).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards at Johns Hopkins Hospital, Baltimore, MD; Bayview Hospital, Baltimore, MD; Howard County General Hospital, Columbia, MD; Suburban Hospital, Bethesda, MD; Sibley Hospital, Washington DC, approved this study as minimal risk and waived informed consent requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable by request